IP Library Granted Patent US 10,272,037
Granted Patent B2
US 10,272,037 · App. 15/707,961 · Granted Apr 30, 2019

Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

Inventors: Ranjan Dohil (San Diego, CA); John Bastian (San Diego, CA); Seema Aceves (Solana Beach, CA); Elaine Phillips (San Diego, CA); Malcolm Hill (Solana Beach, CA)
Assignees: The Regents of the University of California; Meritage Pharma, Inc.
A61K9/0056A61K9/0095A61K9/10A61K31/58A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,037
App. No.
15/707,961
Granted
Apr 30, 2019
Kind
B2
Abstract

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Claims (17)

1. A method for treating an esophageal inflammatory disease in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a solution formed by rapid dissolution of a tablet in a pharmaceutically acceptable liquid; wherein the tablet comprises a therapeutically effective amount of budesonide and polyvinylpyrrolidone; to treat the esophageal inflammatory disease.

2. The method of claim 1 , wherein the method comprises administering about 6 mg per day or less of budesonide.

3. The method of claim 1 , wherein the method comprises administering about 0.5 mg to about 2 mg of budesonide per day.

4. The method of claim 1 , wherein the method comprises administering about 1 mg to about 2mg of budesonide per day.

5. The method of claim 1 , wherein the method comprises administering about 2 mg to about 3 mg of budesonide per day.

6. The method of claim 1 , wherein the method comprises administering about 10 μg to about 400 μg of budesonide per kilogram of the subject per day.

7. The method of claim 1 , wherein the subject is less than 16 years old.

8. The method of claim 1 , wherein the subject is less than 12 years old.

9. The method of claim 1 , wherein the subject is less than 8 years old.

10. The method of claim 1 , wherein the subject is less than 6 years old.

11. The method of claim 1 , wherein the subject is less than 4 years old.

12. The method of claim 1 , wherein the subject is less than 2 years old.

13. The method of claim 1 , wherein the method for treating the esophageal inflammatory disease is a method for treating a symptom of the esophageal inflammatory disease; a method for treating inflammation associated with the esophageal inflammatory disease; or a combination thereof.

14. The method of claim 1 , wherein the method for treating the esophageal inflammatory disease is a method for alleviating a symptom of the esophageal inflammatory disease; a method for alleviating inflammation associated with the esophageal inflammatory disease; or a combination thereof.

15. The method of claim 1 , wherein the esophageal inflammatory disease is eosinophilic esophagitis.

16. The method of claim 1 , wherein the esophageal inflammatory disease is: (i) eosinophilic esophagitis, (ii) an inflammatory bowel disease involving the esophagus, (iii) Crohn's disease, (iv) an esophageal inflammation secondary to ingestion of a caustic or an irritant, (v) a persistent or recurrent esophageal stricture, (vi) pill-induced esophagitis, (vii) a systemic disease, (viii) a congenital disease, or (ix) post-surgery inflammation.

17. The method of claim 16 , wherein the persistent or recurrent esophageal stricture is caused by ingestion of a caustic or an irritant.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Jan 11, 2022
From: MERITAGE PHARMA, INC.; SHIRE VIROPHARMA LLC
To: SHIRE VIROPHARMA LLC
Reel/Frame 058620/0787 →
MERGER AND CHANGE OF NAME Recorded Jan 11, 2022
From: SHIRE VIROPHARMA LLC; VIROPHARMA BIOLOGICS LLC
To: VIROPHARMA BIOLOGICS LLC
Reel/Frame 058625/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: DOHIL, RANJAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 047946/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: BASTIAN, JOHN F; ACEVES, SEEMA
To: CHILDREN'S SPECIALISTS OF SAN DIEGO
Reel/Frame 047946/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: CHILDREN'S SPECIALISTS OF SAN DIEGO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 047946/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: PHILLIPS, ELAINE; HILL, MALCOLM
To: MERITAGE PHARMA, INC.
Reel/Frame 047946/0144 →
Continuity (6)
Division 14147332 · Jan 3, 2014
Continuation 12269572 · Nov 12, 2008
Continuation In Part 11595513 · Nov 9, 2006
Provisional Application 60735340 · Nov 12, 2005
Provisional Application 61090572 · Aug 20, 2008
Related Publication 20180071211A1 · Mar 15, 2018
Cited By (4)
US 12,290,598 US 12,310,976 US 12,447,157 US 12,691,128